| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.069 | 0.02 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.03 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.073 | 0.03 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.084 | 0.03 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.03 |